Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B |
| Cost of revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B | $4.21B |
| Gross profit | $12.70B | $10.78B | $12.07B | $10.47B | $11.08B | $9.34B | $10.71B | $10.25B |
| Gross margin | 74.7% | 71.9% | 72.6% | 66.4% | 71.8% | 70.0% | 70.9% | 70.9% |
| Research and development | $2.34B | $2.47B | $2.58B | $2.32B | $2.13B | $2.07B | $6.77B | $2.13B |
| Selling, general and administrative | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $3.86B | $4.21B |
| Operating expenses | $6.27B | $6.79B | $7.74B | $8.57B | $6.18B | $5.61B | $12.20B | $6.42B |
| Operating income | $6.43B | $3.99B | $4.33B | $1.90B | $4.89B | $3.73B | −$1.50B | $3.83B |
| Operating margin | 37.9% | 26.6% | 26.0% | 12.1% | 31.7% | 28.0% | -9.9% | 26.5% |
| EBITDA | $8.61B | $6.67B | $7.58B | $6.65B | $7.77B | $6.02B | $2.18B | $5.99B |
| Interest income | $0 | −$645.00M | −$655.00M | −$667.00M | $0 | −$627.00M | −$610.00M | −$591.00M |
| Interest expense | −$679.00M | $0 | $0 | — | −$678.00M | $0 | $0 | — |
| Income before taxes | $4.28B | $1.04B | $2.67B | $714.00M | $1.55B | $1.66B | −$2.27B | $2.08B |
| Income taxes | $662.00M | $342.00M | $853.00M | $526.00M | $613.00M | $372.00M | −$2.25B | $520.00M |
| Net income | $3.62B | $697.00M | $1.82B | $188.00M | $941.00M | $1.29B | −$23.00M | $1.56B |
| Net margin | 21.3% | 4.6% | 10.9% | 1.2% | 6.1% | 9.7% | -0.2% | 10.8% |
| EPS, basic | $2.04 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | −$0.02 | $0.88 |
| EPS, diluted | $2.03 | $0.39 | $1.02 | $0.10 | $0.52 | $0.72 | −$0.02 | $0.88 |
| Diluted shares | 1.77B | 1.77B | 1.78B | 1.77B | 1.77B | 1.77B | 1.78B | 1.77B |
Figures describe AbbVie shares, not any token. As of Aug 3, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.